BioLineRx Ltd. (NASDAQ: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has priced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Equity Offerings

BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and WarrantsFebruary 5, 2019 9:02 AM BioLineRx (BLRX) Announces Proposed ADS & Warrants OfferingFebruary 5, 2019 5:40 AM BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and WarrantsFebruary 4, 2019 5:45 PM